ARTICLE | Company News
Ligand's Targretin Gel NDA gets priority review
February 7, 2000 8:00 AM UTC
The FDA granted priority review status to LGND's NDA for its Targretin gel to treat cutaneous T cell lymphoma (CTCL). The company's Targretin capsules were approved to treat CTCL in December 1999. ...